Pre-Market Stocks Roundup: Electronic Arts (NASDAQ:EA), Teck Resources (NYSE:TCK), Jumei International Holding (NYSE:JMEI), Novavax, (NASDAQ:NVAX)

Pre-Market Stocks Roundup: Electronic Arts (NASDAQ:EA), Teck Resources (NYSE:TCK), Jumei International Holding (NYSE:JMEI), Novavax, (NASDAQ:NVAX)

- in Business & Finance
0

On Thursday, Electronic Arts Inc. (NASDAQ:EA)’s shares inclined 1.23% to $65.27.

Electronic Arts Inc. (EA) declared that EA SPORTSTM NHL® 16 will be hitting store shelves on September 15, 2015 in North America and September 17, 2015 in Europe. Built with more fan feedback and insights than ever before, NHL 16 delivers your most requested features and modes together with new experiences that make NHL bigger and better. With new levels of depth across single player and team modes, combined with improved gameplay balance and innovation in addition to new tools to assist you play at your highest level, NHL 16 puts you into the heart of a team, where you’ll play together and win together. Watch the NHL 16 Official E3 gameplay trailer now.

Electronic Arts Inc. develops, markets, publishes, and distributes game software content and online services for video game consoles, Internet-connected consoles, personal computers, mobile phones, and tablets worldwide. The company operates through EA Studios, EA Mobile, and Maxis divisions. It develops and publishes digital interactive entertainment games primarily under the The Sims, Madden NFL, EA SPORTS FIFA, Battlefield, FIFA Soccer, Need for Speed, Dragon Age, and Plants vs. Zombies brand names.

Teck Resources Ltd (USA) (NYSE:TCK)’s shares gained 0.27% to $11.19.

Teck Resources Limited (TCK) was recognized this week as one of the top corporations in Canada for both corporate citizenship and social responsibility in two separate sustainability rankings.

Teck was the fourth-ranked company overall and the top-ranked mining company on the Best 50 Corporate Citizens in Canada ranking by media and investment research company Corporate Knights. Teck was also named one of the Top 50 Socially Responsible Corporations in Canada by Sustainalytics, a global responsible investment research firm.

The Top 50 Socially Responsible Corporations in Canada is a report compiled by Sustainalytics and featured in Maclean’s magazine and L’actualité magazine. Companies were selected on the basis of their performance across key environmental and social indicators within their industries.

This is the third successive year Teck has been named to these two separate sustainability rankings. Earlier this year Corporate Knights also named Teck to the Global 100 Most Sustainable Corporations for the third straight year.

Teck Resources Limited explores, develops, and produces natural resources in the Americas, the Asia Pacific, Europe, and Africa. Its principal products comprise copper, counting copper concentrates and cathode copper; steelmaking coal; and refined zinc and zinc concentrates.

At the end of Thursday’s trade, Jumei International Holding Ltd (ADR) (NYSE:JMEI)‘s shares dipped -1.08% to $24.70.

Jumei International Holding Ltd (ADR) (JMEI) declared that it has attained a minority stake in It’S SKIN, a Korean beauty brand.

It’S SKIN is a prestige Korean beauty brand that has become very popular amongst Chinese consumers.

Mr. Leo Ou Chen, founder and CEO of Jumei, stated, The popularity of Korean beauty products in China has grown rapidly over the past few years. With an extensive catalogue of prestige products, It’S SKIN is an ideal partner for Jumei to collaborate with as we build Jumei Global into the largest cross border e-commerce platform in China. It’S SKIN will greatly benefit from the growing size and scale of our platform.

Jumei International Holding Limited operates as an online retailer of beauty products in the People’s Republic of China. The company offers beauty products, such as cosmetics, skin care, cosmetic applicators, fragrance, and body care products; and beauty products for men, and baby and children.

Novavax, Inc. (NASDAQ:NVAX), ended its Thursday’s trading session with 4.38% gain, and closed at $9.53.

Novavax, Inc. (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared the appointment of Gail K. Boudreaux to its Board of Directors.

Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience comprises more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is presently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 

Leave a Reply

Your email address will not be published. Required fields are marked *